Trade Mark Journal No.2025/028 11 July 2025
WO0000001850156 (1,5,9,42,44)
Office of origin: United States of America
Date of International Registration:19 December 2024
Date of designation in the UK:
19 December 2024
International priority date claimed: 18 December 2024
(United States of America)
(98910311)
- Class 1
- Chemical and biological reagents for scientific research, drug discovery, and drug development; sequencing reagents; optical screening reagents; cell imaging reagents; biochemical assay kits for laboratory use; reagents for laboratory automation systems and scientific apparatus; chemical preparations for high-throughput screening; laboratory chemicals and solutions for research purposes, excluding those for medical use, including reagents supporting artificial intelligence-driven workflows and machine learning applications.
- Class 5
- Pharmaceutical preparations and substances for human and veterinary use for the treatment and prevention of diseases; biological and chemical preparations for medical and therapeutic use; diagnostic reagents and testing kits for medical purposes; nucleic acid-based therapeutics, small molecule drugs, and biologics; pharmaceutical products informed by predictive modeling and data analysis using machine learning and artificial intelligence; precision medicine drug delivery formulations; pharmaceutical drugs; drugs for medical purposes; medicines for human purposes.
- Class 9
- Laboratory automation systems and hardware for scientific research, drug discovery, and drug development; optical screening devices; cell imaging instruments; DNA sequencing machines; robotic laboratory systems; biosensors; high-throughput screening devices; laboratory instruments for measuring, analyzing, and monitoring biological and chemical samples; AI-powered hardware and software for scientific and laboratory applications, including experimental data generation; devices for sale or licensing to research organizations and pharmaceutical companies.
- Class 42
- Scientific and technological research and development services in the fields of drug discovery, pharmaceutical development, and biotechnology; providing artificial intelligence (AI) and machine learning (ML) platforms for scientific and medical research; development of computer software and computational tools for drug discovery, genomics, and data analysis; laboratory research services using automation, high-throughput experimentation, and data modeling; software as a service (SaaS) featuring AI-powered drug discovery, predictive modeling, and biological data analysis; development of proprietary algorithms for scientific and medical research; multi-omics data integration services for therapeutic discovery; consulting services in computational biology and AI-driven drug discovery; medical research.
- Class 44
- Medical consulting services; personalized medicine services, including diagnostic and therapeutic recommendations; healthcare services utilizing artificial intelligence for disease prediction, patient stratification, and management; drug discovery and development support services from a medical perspective; medical analysis services for diagnostic and treatment purposes; providing medical information and consultancy related to therapeutic research and development; clinical trial support and patient stratification services informed by computational biology; digital health solutions integrating data-driven medical insights; medical services; health consultancy; healthcare services; medical treatment services for diseases; healthcare advisory services; collation of information in the healthcare sector, namely, the development and collation of disease knowledge data sets; pharmaceutical advice; medical clinic services; medical advice for individuals with diseases; advisory services relating to diseases; advisory services relating to treatment of diseases; provision of medicine in the field of diseases, namely, developing treatments for unmet medical needs.
Insitro, Inc.
Representative: Abion UK, 33 Gutter Lane London EC2V 8AS UNITED KINGDOM